A recent study has suggested that the brain-expressed genes for G72 and D-amino-acid oxidase (DAAO) exert an influence on susceptibility to schizophrenia. Our aim was to replicate this finding in German schizophrenic patients and to assess whether G72 and DAAO might also contribute to the development of bipolar affective disorder. We genotyped seven single-nucleotide polymorphisms (SNPs) in the G72 gene and three in the DAAO gene in 599 patients (299 schizophrenic, 300 bipolar) and 300 controls. At G72, individual SNPs and a four-marker haplotype were associated with schizophrenia. The most significant SNP as well as the haplotype were also associated with bipolar affective disorder (BPAD). DAAO was associated with schizophrenia, but not with BPAD. The association of variation at G72 with schizophrenia as well as BPAD provides molecular support for the hypothesis that these two major psychiatric disorders share some of their etiologic background. Molecular Psychiatry (2004Psychiatry ( ) 9, 203-207. doi:10.1038 Over the past decade, inconsistency in linkage findings as well as a host of nonreplications of 'candidate gene' association studies seemed to be the inevitable fate of genetic research in psychiatry, preventing any major breakthrough. Recently, however, the progress of the human genome project and the development of high-throughput genotyping technology have laid the foundations for a more efficient search for the involved genes. As a result of this development, systematic fine mapping in wellestablished linkage regions and replications of association findings have identified Dysbindin and Neuregulin-1 as genetic factors contributing to the etiology of schizophrenia.
Over the past decade, inconsistency in linkage findings as well as a host of nonreplications of 'candidate gene' association studies seemed to be the inevitable fate of genetic research in psychiatry, preventing any major breakthrough. Recently, however, the progress of the human genome project and the development of high-throughput genotyping technology have laid the foundations for a more efficient search for the involved genes. As a result of this development, systematic fine mapping in wellestablished linkage regions and replications of association findings have identified Dysbindin and Neuregulin-1 as genetic factors contributing to the etiology of schizophrenia. [1] [2] [3] [4] Recently, an association of the newly identified brain-expressed protein G72 and its likely interaction partner D-amino-acid oxidase (DAAO) with schizophrenia was suggested by the analysis of single-nucleotide polymorphisms (SNPs) in the respective genes. 5 Both genes are located in chromosomal regions showing evidence for linkage with the disorder (G72 on 13q32-33; DAAO on 12q24). 6 Given the importance of independent observation of association findings in genetically complex diseases such as schizophrenia, we aimed at replicating these findings in an independent sample of schizophrenic patients and controls from Germany. Furthermore, we hypothesized that G72 and DAAO might also contribute to the development of bipolar affective disorder (BPAD) for two reasons: first, although schizophrenia and BPAD are characterized by distinct clinical patterns of symptoms, a variety of psychopathological features are shared between these two disease entities. This has brought forward the hypothesis of a shared etiologic background. 7 Second, linkage findings in the chromosomal regions harboring the genes for G72 and DAAO have also been reported for BPAD. [8] [9] [10] [11] We genotyped seven SNPs in the G72 gene and three SNPs in the DAAO gene. Our samples comprised 299 patients suffering from schizophrenia, 300 patients with BPAD, and a population-based sample of 300 healthy controls.
Of the seven G72 variants typed, four SNPs (M12, M15, M23 and M24) proved to be in significant linkage disequilibrium with schizophrenia, the strongest evidence being observed for M23 (P¼0.033 for allele frequencies) ( Table 1 ). The same SNP was significantly associated with BPAD (P¼0.013 for allele frequencies) ( Table 1 ). Haplotype analysis strengthened the statistical significance for schizophrenia and-to a lesser extent-also for BPAD. We tested the four-locus haplotype M12-M15-M23-M24 and found that it was associated with schizophrenia (global, P¼0.032) ( Table 2 ). Individual comparison of the common haplotypes showed that haplotype M12-M15-M23-M24 (C-G-T-A) was less frequent in schizophrenic patients (P¼0.00023). The same haplotype was also significantly less frequent in patients (odds ratio) Odds ratios are calculated using the more frequent alleles in affected individuals compared to controls.
with BPAD (P¼0.032), but the global P-value did not reach significance (P¼0.08) ( Table 2 ). It should be noted that M12 and M15 as well as M23 and M24 show a high degree of intermarker LD (Table 3) in our study.
The three SNPs in the DAAO gene were associated with schizophrenia, but failed to reach statistical significance in the BPAD sample (Table 1) . At the haplotype level, the three-locus haplotype MDAAO4-MDAAO5-MDAAO6 gave a significant global P-value in schizophrenia (global, P¼0.042), but not BPAD (global, P¼0.325) ( Table 2) .
It should be noted that the schizophrenia-associated haplotype that we observed for G72 is different from that reported by Chumakov et al. 5 We confirmed the identity of the associated haplotypes in our sample by sequencing homozygous genotypes at the 10-marker loci. A comparison of our results to the study published by Hattori et al. 12 shows that five identical SNPs were analyzed in the two studies: rs1341402, rs2391191 [M15], rs1935062, rs778294 [M19] and M23. Of these, rs1341402, rs1935062 and rs778294 [M19] produced significant results in the single-marker analysis of Hattori et al, 12 but not in our study. On the other hand, rs2391191
[M15] and M23 were significant in our analysis, but not in their study. A possible explanation for this observation could be the presence of different risk haplotypes in the populations under study, as has been reported for Dysbindin and schizophrenia. 1, 2 It is also worth noting that the association of haplotype M12-M15-M23-M24 with schizophrenia and BPAD is mainly due to a highly significant underrepresentation of the very same haplotype (C-G-T-A) in affected individuals as compared to controls. This might be explained by a protective effect of this haplotype.
Comparison of our results for the MDAAO-SNPs with the data reported by Chumakov et al
5 reveals that the association of MDAAO4 and MDAAO5 is in the opposite direction. While we find a significant increase of the more frequent SNP alleles, Chumakov et al 5 observed an increase of the rarer SNP alleles. For MDAAO6, both studies find a significant increase of the rarer allele.
Confirming functional molecular data, Chumakov et al 5 found statistical evidence for an interaction between G72 and DAAO. Using logistic regression analysis, we tested different models of interaction for schizophrenia as well as for BPAD. The obtained odds ratios, however, did not favor a multiplicative/interactive effect over an additive effect (data not shown).
In conclusion, our results suggest that variability in the G72 and DAAO genes is involved in the etiology of schizophrenia in the German population. Our findings independently confirm the report of an association of G72 with schizophrenia in the French Canadian and Russian population. 5 Moreover, our study provides evidence that variability in G72 contributes to the development of BPAD. This is in accordance with a study by Hattori et al., 12 who report an association of G72 with BPAD in two independent samples of US-American descent. There is no strong evidence for an involvement of DAAO in the etiology of BPAD in our sample, although a small effect cannot be excluded. Definitive conclusions will require the investigation of larger samples or the investigation of samples that could represent genetically more homogeneous subgroups of the disorder (eg early-onset bipolar disorder 13 ). Based on our results, G72 seems to contribute to the risk for schizophrenia and BPAD via the same pathological pathway. Further studies will explore the correlation between risk haplotypes and pheno- These findings may open a door to a more precise classification of these two major disorders.
Materials and methods

Subjects
All individuals included in the study were of German descent and recruited in the same geographical area. Patients were systematically ascertained at the Department of Psychiatry at the University of Bonn. Written informed consent was obtained from all patients and controls. All patients had been interviewed by experienced psychiatrists using the Structured Clinical Interview for DSM-IV Disorders.
14 Lifetime 'best estimate' diagnoses according to DSM-IV criteria 15 were based on multiple sources of information, including personal structured interview (SCID I), medical records, and family history method. Consensus diagnoses were performed by two psychiatrists, and whenever necessary, more psychiatrists were included in the decision process. The 299 schizophrenic patients comprised 151 males and 148 females (mean age of 38.6711.9 years); the 300 BPAD cases consisted of 138 males and 162 females (mean age of 42.3713.2 years). The 300 controls comprised 121 males and 179 females (mean age of 47.1715.2 years).
Genotyping and statistical analysis Seven SNPs were genotyped in the G72 gene (M12 rs1341402, M15 (rs2391191), rs1935062, M19 (rs778294), M23, M24), 5, 12 and three in the DAAO gene (MDAAO4, MDAAO5, MDAAO6). 5 Genotypes were determined by Masscodet Technology (QIAGEN Genomics). Genotype frequencies for cases and controls were in Hardy-Weinberg equilibrium. Singlemarker and haplotype-based analyses were performed. For the single-marker analysis, we used the Armitage trend test (allelewise analysis) and the standard w 2 test (genotypewise analysis). For the comparison of haplotype frequencies between cases and controls, we used the computer program FAM-HAP. 16 FAMHAP estimates haplotype frequencies using an expectation-maximization algorithm. Haplotype frequencies in cases and controls are then compared in a global-likelihood-ratio w 2 test. To overcome the uncertainty of the w 2 approximation, we verified the validity of the P-values with the simulation feature of the program. Pairwise LD measures D 0 and r 2 were calculated from the estimated haplotype frequencies. 17 Due to the high degree of intermarker linkage disequilibrium, a Bonferroni correction for multiple testing would be too conservative. Therefore, uncorrected P-values are given. 
